In Vivo Evaluation of Sepigel-Based Meglumine Antimoniate and Amphotericin B for Cutaneous Leishmaniasis Treatment

López-Arencibia, Atteneri; Bethencourt-Estrella, Carlos J.; Berenguer, Diana; Domínguez-de-Barros, Angélica; Alcover, M. Magdalena; Sessa, Marcella; Halbaut, Lyda; Fisa, Roser; Calpena-Campmany, Ana Cristina; Córdoba-Lanús, A. Elizabeth; Lorenzo-Morales, Jacob; Riera, Cristina; Piñero, José E.

doi:10.3390/pathogens13080712

Open AccessArticle

In Vivo Evaluation of Sepigel-Based Meglumine Antimoniate and Amphotericin B for Cutaneous Leishmaniasis Treatment

by

Atteneri López-Arencibia

^1,2,3,*

,

Carlos J. Bethencourt-Estrella

¹,

Diana Berenguer

⁴,

Angélica Domínguez-de-Barros

¹

,

M. Magdalena Alcover

⁴

,

Marcella Sessa

⁵,

Lyda Halbaut

⁵

,

Roser Fisa

⁴

,

Ana Cristina Calpena-Campmany

⁵

,

A. Elizabeth Córdoba-Lanús

^1,2

,

Jacob Lorenzo-Morales

^1,2,3,

Cristina Riera

^4,*

and

José E. Piñero

^1,2,3

¹

Instituto Universitario de Enfermedades Tropicales y Salud Pública de Canarias (IUETSPC), Universidad de La Laguna (ULL), Avenida Astrofísico Francisco Sánchez s/n, 38206 La Laguna, Tenerife, Spain

²

Consorcio Centro de Investigación Biomédica en Red M.P. de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, 28006 Madrid, Spain

³

Departamento de Obstetricia y Ginecología, Pediatría, Medicina Preventiva y Salud Pública, Toxicología, Medicina Legal y Forense y Parasitología, Universidad de La Laguna (ULL), 38200 Santa Cruz de Tenerife, Tenerife, Spain

⁴

Department of Biology, Health and Environment, Laboratory of Parasitology, Faculty of Pharmacy and Food Sciences, University of Barcelona, 08028 Barcelona, Spain

⁵

Department of Pharmaceutical Technology and Physicochemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, 08028 Barcelona, Spain

^*

Authors to whom correspondence should be addressed.

Pathogens 2024, 13(8), 712; https://doi.org/10.3390/pathogens13080712

Submission received: 18 July 2024 / Revised: 16 August 2024 / Accepted: 19 August 2024 / Published: 22 August 2024

(This article belongs to the Special Issue Opportunistic and Rare Parasitic Infections)

Download

Browse Figures

Versions Notes

Abstract

Cutaneous leishmaniasis (CL) poses a significant public health concern in endemic regions due to its increasing prevalence and substantial impact on affected individuals. This disease is primarily caused by the Leishmania protozoa, which are transmitted through insect bites, and it manifests as a range of symptoms, from self-healing lesions to severe disfigurement. Current treatments, which often involve the parenteral administration of antimonials, face challenges such as poor compliance and adverse effects. This study investigates the efficacy of topical formulations containing meglumine antimoniate (MA) and amphotericin B (AmB), using Sepigel as an excipient, for treating CL. In the in vivo study, BALB/c mice infected with L. amazonensis developed lesions at the injection site five weeks post-infection. Subsequently, the mice were divided into eight groups: untreated mice, mice treated orally with miltefosine, mice treated intraperitoneally with MA, and mice treated topically with 15%, 22.5%, and 30% MA-Sepigel, as well as those treated with AmB-Sepigel. Treatments were applied daily for two weeks, and the results revealed a significant reduction in lesion size and parasite burden following topical application, particularly with the AmB-Sepigel formulations and 30% MA-Sepigel. Additionally, Sepigel-based treatments demonstrated improved patient compliance and reduced toxicity compared to systemic therapies. These findings underscore the potential of Sepigel-based formulations as a promising alternative for CL treatment. They offer enhanced efficacy and tolerability, while reducing the systemic toxicity associated with conventional therapies.

Keywords: Leishmania amazonensis; in vivo; meglumine antimoniate; amphotericin B; Sepigel

Share and Cite

MDPI and ACS Style

López-Arencibia, A.; Bethencourt-Estrella, C.J.; Berenguer, D.; Domínguez-de-Barros, A.; Alcover, M.M.; Sessa, M.; Halbaut, L.; Fisa, R.; Calpena-Campmany, A.C.; Córdoba-Lanús, A.E.; et al. In Vivo Evaluation of Sepigel-Based Meglumine Antimoniate and Amphotericin B for Cutaneous Leishmaniasis Treatment. Pathogens 2024, 13, 712. https://doi.org/10.3390/pathogens13080712

AMA Style

López-Arencibia A, Bethencourt-Estrella CJ, Berenguer D, Domínguez-de-Barros A, Alcover MM, Sessa M, Halbaut L, Fisa R, Calpena-Campmany AC, Córdoba-Lanús AE, et al. In Vivo Evaluation of Sepigel-Based Meglumine Antimoniate and Amphotericin B for Cutaneous Leishmaniasis Treatment. Pathogens. 2024; 13(8):712. https://doi.org/10.3390/pathogens13080712

Chicago/Turabian Style

López-Arencibia, Atteneri, Carlos J. Bethencourt-Estrella, Diana Berenguer, Angélica Domínguez-de-Barros, M. Magdalena Alcover, Marcella Sessa, Lyda Halbaut, Roser Fisa, Ana Cristina Calpena-Campmany, A. Elizabeth Córdoba-Lanús, and et al. 2024. "In Vivo Evaluation of Sepigel-Based Meglumine Antimoniate and Amphotericin B for Cutaneous Leishmaniasis Treatment" Pathogens 13, no. 8: 712. https://doi.org/10.3390/pathogens13080712

APA Style

López-Arencibia, A., Bethencourt-Estrella, C. J., Berenguer, D., Domínguez-de-Barros, A., Alcover, M. M., Sessa, M., Halbaut, L., Fisa, R., Calpena-Campmany, A. C., Córdoba-Lanús, A. E., Lorenzo-Morales, J., Riera, C., & Piñero, J. E. (2024). In Vivo Evaluation of Sepigel-Based Meglumine Antimoniate and Amphotericin B for Cutaneous Leishmaniasis Treatment. Pathogens, 13(8), 712. https://doi.org/10.3390/pathogens13080712

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Menu

In Vivo Evaluation of Sepigel-Based Meglumine Antimoniate and Amphotericin B for Cutaneous Leishmaniasis Treatment

Abstract

Share and Cite

Article Metrics

Article Access Statistics

Further Information

Guidelines

MDPI Initiatives

Follow MDPI